Fizy health
Refill pricing structure

Is Refill pricing pass-through or marked up?

Refill is not a per-line 503A pass-through platform. It negotiates aggregate pre-negotiated medication rates across its pharmacy network and charges tiered software fees on transactions, published at roughly 1.5–5% depending on platform plan, plus monthly platform subscriptions on published tiers. Medication cost reflects network leverage rather than disclosed per-vial 503A cost from the compounder. Refill advertises a meet-or-beat guarantee on aggregate rates, but the split between drug cost and platform economics is not shown as separate pass-through lines before checkout.

This page explains the difference between aggregate-plus-fee pricing and true pass-through, and why the distinction matters when you quote cash-pay patients.

Compare Fizy Health vs Refill
Aggregate vs pass-through Software fees 1.5–5% Not per-line 503A cost Meet-or-beat guarantee Margin transparency Disclosed facilitation fee

Pass-through, aggregate, and markup: three different ideas

Pass-through pricing shows the 503A compounder's per-vial cost on each line before checkout, with platform economics disclosed separately. Aggregate pricing negotiates medication cost across pooled network volume and presents a blended rate to clinics, which may or may not equal underlying compounder cost. Markup adds margin on top of drug cost inside an opaque rate. Refill's public model is aggregate pre-negotiated pricing plus explicit software fees on transactions, not per-line pass-through. That is a legitimate structure when network leverage wins, but it is not the same as answering whether your semaglutide line is base 503A cost or marked up, because the medication rate and software fee are different layers than pass-through disclosure.

What clinics can and cannot verify on Refill

You can verify published platform tiers, software fee ranges, Refill Connect pricing, and provider encounter fees at about $30 hands-on or $50 hands-off. You can verify meet-or-beat guarantee terms at demo. What you typically cannot verify without onboarding is whether the aggregate medication rate on a given SKU equals the underlying 503A compounder invoice cost, because Refill does not show per-line pass-through from partner to clinic on a public catalog.

That matters when patients ask whether your cash-pay price is fair or when you compare pharmacy partners. Aggregate pricing optimizes network leverage. Pass-through pricing optimizes margin transparency. Both can be honest; they solve different clinic questions.

When pass-through visibility is the better fit

Fizy Health is built for clinics with in-house prescribers who need to answer what does this vial cost me before the consult. Resolved per-vial 503A cost shows on each catalog and cart line before checkout, with a disclosed facilitation fee at payment. Drug cost and platform fee are separate visible lines, not a blended aggregate rate plus percentage software fee.

Choose Refill when aggregate leverage plus bundled telehealth infrastructure beats pass-through on your top SKUs after all fees, and you accept that medication economics are confirmed at demo. Choose Fizy Health when margin clarity, batch refill-day checkout, and per-line cost before payment are how your team runs.

Buy aggregate leverage — or buy pass-through transparency?

Refill fits if

Refill

Aggregate network pricing plus infrastructure beats transparency trade-offs.

  • Pre-negotiated aggregate rates beat pass-through on your top SKUs after software fees at your volume.
  • You need Refill Connect or outsourced prescribing and accept tiered transaction fees.
  • Meet-or-beat terms give you confidence without needing per-line compounder pass-through.
Consider Fizy Health if

Fizy Health

You prescribe in-house and need to see 503A cost per line.

  • You quote cash-pay patients and need resolved per-vial 503A cost before checkout.
  • You want drug cost and facilitation fee separate, not aggregate rate plus percentage software fee.
  • You compare pharmacy partners on the same SKU with visible per-line economics.
If you choose Fizy Health

What you get when pass-through is the model.

Refill uses aggregate plus software fees. These outcomes come from per-line pass-through disclosure.

See all features
Keep evaluating Refill pricing

More on Refill pricing structure.

See the full Refill pricing guide
FAQ

What clinics ask about Refill pass-through vs markup.

  • Model

    Is Refill pass-through pricing?

    No. Refill uses aggregate pre-negotiated 503A medication pricing plus tiered software fees on transactions, not per-line disclosed 503A pass-through from compounder to clinic before checkout.

  • Markup

    Does Refill mark up drug pricing?

    Refill negotiates aggregate network rates rather than showing underlying compounder cost per line. Software fees on transactions are published separately within roughly 1.5–5% on tiered plans. The medication layer is network-negotiated, not pass-through disclosed.

  • Verification

    Can I see base 503A cost on Refill?

    Refill confirms per-SKU aggregate rates at demo rather than on a public pass-through catalog. You see the rate Refill offers, not necessarily the underlying compounder invoice broken out per line.

  • Guarantee

    Does meet-or-beat replace pass-through transparency?

    It addresses competitiveness against other quotes, not per-line margin transparency. You still model aggregate rate plus software fees rather than reading compounder pass-through on each cart line.

  • Comparison

    How is Fizy Health different?

    Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout with a disclosed facilitation fee at payment, separating drug cost from platform economics explicitly.

  • Fit

    When does aggregate pricing beat pass-through?

    When pre-negotiated network rates plus fees beat visible pass-through on your top SKUs at your volume and you need bundled telehealth infrastructure. Model all-in cost honestly rather than assuming aggregate always wins.

Sources reviewed June 2026

  • Refill public website and published pricing tiers in Refill web app (refill.co), reviewed June 2026.
  • Fizy Health platform capabilities reflect the live product.
Evaluate with real numbers

See 503A cost per line before you quote patients.

Compare pass-through landed cost on your top SKUs against any aggregate quote, then decide with transparent margin math. Free to start.

Start Ordering Free Fizy Health vs Refill